Współczesna Onkologia

Molecularly guided treatment in recurrent mucinous ovarian carcinoma

Olga Meneses 1
,
Ana Maria Alzamora 2
,
Carla Renata Dias 2
,
Miguel Henriques Abreu 1

  1. Medical Oncology Department, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

  2. Pathology Department, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

Contemp Oncol (Pozn) 2026; 30 (3)

DOI: https://doi.org/10.5114/wo.2026.163809
Data publikacji online: 2026/09/11
Article file
Molecularly guided.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
  2. Hess V, A’Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044.
  3. Sahraoui G, Fitouri A, Charfi L, Driss M, Slimane M, Hechiche M, et al. Mucinous borderline ovarian tumors: pathological and prognostic study at Salah Azaiez Institute. Pan Afr Med J 2022; 41: 349.
  4. Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 2013; 229: 111-120.
  5. Smithgall MC, Yemelyanova A, Mathew S, Gogineni S, He B, Zhang T, et al. HER2/ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors. Int J Gynecol Pathol 2024; 43: 134-139.
  6. Chay WY, Chew SH, Ong WS, Busmanis I, Li X, Thung S, et al. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One 2013; 8: e61565.
  7. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2023; 41: 4065-4076.
  8. Han R, Madariaga A, Gonzalez-Ochoa E, Smith AC, Wang L, Lheureux S, et al. HER2-low and overexpression in mucinous ovarian cancer: analysis of ASCO/CAP and ToGA immunohistochemical scoring. Int J Gynecol Pathol 2024; 43: 275-283.
  9. Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med 2015; 7: 87.
  10. Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer 2015; 15: 415.
  11. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003; 90: 378-381.
  12. Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med 2019; 380: 1256-1266.
  13. Zhang Y, Barkdull S, Kontoyiannis PD, Legarreta AF, Gershen- son DM, Ramalingam P, et al. TP53 and KRAS co-mutations are associated with worse outcomes in mucinous ovarian carcinomas. Front Oncol 2025; 15: 1573801.
  14. Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 2008; 99: 2020-2028.
  15. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low metastatic breast cancer. N Engl J Med 2022; 387: 9-20.
  16. Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-pantumor02 phase II trial. J Clin Oncol 2024; 42: 47-58.
  17. Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 2020; 38: 1222-1245.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications